Grit Bio is a cutting-edge biotechnology company focused on the development of novel therapeutics for unmet medical needs. The company leverages advanced technologies and scientific research to create innovative solutions for patients across various disease areas.

Grit Biotechnology

Grit Bio

Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor. GT101 - Grit’s non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial.  Grit Bio has established three core technology platforms for its TIL development: StaViral® - a retroviral system tailored for TIL engineering, ImmuT Finder® - a high-throughput screening platforms identifying novel T-cell targets, and TIL expansion platform StemTexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.

COM:GRIT-BIO

Grit Bio

locale

market

industry

website

crunchbase

linkedin

peer of

investor of

Metrics